Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prednisone for idiosyncratic drug-induced liver injury with hepatotoxicity
2024-513004-33-00Phase 2Authorised
- Sponsor
- Fundación IMABIS
- Start
- Jan 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Drug-induced hepatitis (DILI) comparing Prednisone arm with Placebo arm (2 arms). Primary endpoints: Total bilirubin response at day 14, Time to bilirubin normalization and 1 more. Planned start Jan 2025; status: authorised.
02
Drugs
prednisone
03
Conditions
Drug-induced hepatitis (DILI)
Beyond the preview
Go deeper on 2024-513004-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513004-33-00.